U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C7H15Cl2N2O2P.H2O
Molecular Weight 279.101
Optical Activity ( + / - )
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYCLOPHOSPHAMIDE

SMILES

O.ClCCN(CCCl)P1(=O)NCCCO1

InChI

InChIKey=PWOQRKCAHTVFLB-UHFFFAOYSA-N
InChI=1S/C7H15Cl2N2O2P.H2O/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14;/h1-7H2,(H,10,12);1H2

HIDE SMILES / InChI

Molecular Formula C7H15Cl2N2O2P
Molecular Weight 261.086
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Cyclophosphamide (the generic name for Cytoxan, Neosar, Revimmune), also known as cytophosphane, is a nitrogen mustard alkylating agent, from the oxazophorines group. It is used to treat various types of cancer and some autoimmune disorders. It is a "prodrug"; it is converted in the liver to active forms that have chemotherapeutic activity

Originator

Curator's Comment: Cyclophosphamide was developed by Norbert Brock and ASTA (now Baxter Oncology).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Primary
CYTOXAN

Approved Use

To treat Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma and minimal Change Nephrotic Syndrome in Pediatric Patients.

Launch Date

-3.06806391E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1234 μg/L
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: Imatinib | Bevacizumab
CYCLOPHOSPHAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
17587 μg × h/L
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: Imatinib | Bevacizumab
CYCLOPHOSPHAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.8 h
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: Imatinib | Bevacizumab
CYCLOPHOSPHAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
80%
CYCLOPHOSPHAMIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg/m2 2 times / day multiple, intravenous
MTD
Dose: 200 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 5
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 5
Sources: Page: p.5, 16
Other AEs: Bilirubin total increased, Diarrhea...
Other AEs:
Bilirubin total increased (grade 3, 20%)
Diarrhea (grade 3, 20%)
Sources: Page: p.5, 16
300 mg/m2 2 times / day multiple, intravenous
Studied dose
Dose: 300 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 25
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 25
Sources: Page: p.5, 16
DLT: Diarrhea, Lipase increased...
Dose limiting toxicities:
Diarrhea (grade 3-5, 12%)
Lipase increased (grade 4, 4%)
Transaminases increased (grade 3-5, 12%)
Nausea and vomiting (grade 3-5, 4%)
Sources: Page: p.5, 16
3300 mg/m2 single, intravenous
Highest studied dose
Dose: 3300 mg/m2
Route: intravenous
Route: single
Dose: 3300 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
DLT: Neutropenia, Thrombocytopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 33.3%)
Thrombocytopenia (16.7%)
Neutropenia (16.7%)
Sources: Page: p.98
2700 mg/m2 single, intravenous
MTD
Dose: 2700 mg/m2
Route: intravenous
Route: single
Dose: 2700 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
DLT: Neutropenia, Thrombocytopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 16.7%)
Thrombocytopenia (16.7%)
Neutropenia (16.7%)
Sources: Page: p.98
2000 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2000 mg/m2, 1 times / 3 weeks
Co-administed with::
paclitaxel, i.v(200 mg/m2, once in 3 weeks, 5 cycles)
Sources: Page: p.658
unhealthy, 27 - 70
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 27 - 70
Sex: F
Population Size: 6
Sources: Page: p.658
DLT: Febrile neutropenia, Thrombocytopenia...
Dose limiting toxicities:
Febrile neutropenia (33.3%)
Thrombocytopenia (grade 4, 16.7%)
Sources: Page: p.658
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles)
Sources: Page: p.519
unhealthy, 47-78
n = 6
Health Status: unhealthy
Condition: Urothelial bladder cancer
Age Group: 47-78
Sex: M+F
Population Size: 6
Sources: Page: p.519
DLT: Neutropenia, Thrombocytopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 33.3%)
Thrombocytopenia (grade 4, 16.7%)
Constipation (grade 3, 16.7%)
Sources: Page: p.519
50 mg 1 times / day multiple, oral
MTD
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
paclitaxel, i.v(175 mg/m(2) (Day 1), 12 cycles)
Sources: Page: p.519
unhealthy, 47-78
n = 6
Health Status: unhealthy
Condition: Urothelial bladder cancer
Age Group: 47-78
Sex: M+F
Population Size: 6
Sources: Page: p.519
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Disc. AE: Myelosuppression, Immunosuppression...
AEs leading to
discontinuation/dose reduction:
Myelosuppression
Immunosuppression
Bone marrow failure
Infection
Urinary tract toxicity
Toxicity renal
Cystitis hemorrhagic
Pyelitis
Ureteritis
Hematuria
Cardiotoxicity
Myocarditis
Myopericarditis
Pericardial effusion
Arrhythmia (NOS)
Congestive heart failure
Pulmonary toxicity
Pneumonitis
Pulmonary fibrosis
Pulmonary veno-occlusive disease
Respiratory failure
Metastases
Venoocclusive liver disease
Fetal damage
Sources: Page: p.1
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Disc. AE: Myelosuppression, Immunosuppression...
AEs leading to
discontinuation/dose reduction:
Myelosuppression
Immunosuppression
Bone marrow failure
Infection
Urinary tract toxicity
Toxicity renal
Cystitis hemorrhagic
Pyelitis
Ureteritis
Hematuria
Cardiotoxicity
Myocarditis
Myopericarditis
Pericardial effusion
Arrhythmia (NOS)
Congestive heart failure
Pulmonary toxicity
Pneumonitis
Pulmonary fibrosis
Pulmonary veno-occlusive disease
Respiratory failure
Metastases
Venoocclusive liver disease
Fetal damage
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Bilirubin total increased grade 3, 20%
200 mg/m2 2 times / day multiple, intravenous
MTD
Dose: 200 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 5
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 5
Sources: Page: p.5, 16
Diarrhea grade 3, 20%
200 mg/m2 2 times / day multiple, intravenous
MTD
Dose: 200 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 5
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 5
Sources: Page: p.5, 16
Diarrhea grade 3-5, 12%
DLT
300 mg/m2 2 times / day multiple, intravenous
Studied dose
Dose: 300 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 25
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 25
Sources: Page: p.5, 16
Transaminases increased grade 3-5, 12%
DLT
300 mg/m2 2 times / day multiple, intravenous
Studied dose
Dose: 300 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 25
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 25
Sources: Page: p.5, 16
Nausea and vomiting grade 3-5, 4%
DLT
300 mg/m2 2 times / day multiple, intravenous
Studied dose
Dose: 300 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 25
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 25
Sources: Page: p.5, 16
Lipase increased grade 4, 4%
DLT
300 mg/m2 2 times / day multiple, intravenous
Studied dose
Dose: 300 mg/m2, 2 times / day
Route: intravenous
Route: multiple
Dose: 300 mg/m2, 2 times / day
Co-administed with::
Clofarabine, i.v(40 mg/m(2) daily × 3 days)
Sources: Page: p.5, 16
unhealthy, 21-72
n = 25
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 21-72
Sex: M+F
Population Size: 25
Sources: Page: p.5, 16
Neutropenia 16.7%
DLT
3300 mg/m2 single, intravenous
Highest studied dose
Dose: 3300 mg/m2
Route: intravenous
Route: single
Dose: 3300 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Thrombocytopenia 16.7%
DLT
3300 mg/m2 single, intravenous
Highest studied dose
Dose: 3300 mg/m2
Route: intravenous
Route: single
Dose: 3300 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Neutropenia grade 4, 33.3%
DLT
3300 mg/m2 single, intravenous
Highest studied dose
Dose: 3300 mg/m2
Route: intravenous
Route: single
Dose: 3300 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Neutropenia 16.7%
DLT
2700 mg/m2 single, intravenous
MTD
Dose: 2700 mg/m2
Route: intravenous
Route: single
Dose: 2700 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Thrombocytopenia 16.7%
DLT
2700 mg/m2 single, intravenous
MTD
Dose: 2700 mg/m2
Route: intravenous
Route: single
Dose: 2700 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Neutropenia grade 4, 16.7%
DLT
2700 mg/m2 single, intravenous
MTD
Dose: 2700 mg/m2
Route: intravenous
Route: single
Dose: 2700 mg/m2
Co-administed with::
paclitaxel, i.v(160 mg/m2)
Sources: Page: p.98
unhealthy, 26-64
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 26-64
Sex: F
Population Size: 6
Sources: Page: p.98
Febrile neutropenia 33.3%
DLT
2000 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2000 mg/m2, 1 times / 3 weeks
Co-administed with::
paclitaxel, i.v(200 mg/m2, once in 3 weeks, 5 cycles)
Sources: Page: p.658
unhealthy, 27 - 70
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 27 - 70
Sex: F
Population Size: 6
Sources: Page: p.658
Thrombocytopenia grade 4, 16.7%
DLT
2000 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 2000 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 2000 mg/m2, 1 times / 3 weeks
Co-administed with::
paclitaxel, i.v(200 mg/m2, once in 3 weeks, 5 cycles)
Sources: Page: p.658
unhealthy, 27 - 70
n = 6
Health Status: unhealthy
Condition: Breast cancer
Age Group: 27 - 70
Sex: F
Population Size: 6
Sources: Page: p.658
Constipation grade 3, 16.7%
DLT
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles)
Sources: Page: p.519
unhealthy, 47-78
n = 6
Health Status: unhealthy
Condition: Urothelial bladder cancer
Age Group: 47-78
Sex: M+F
Population Size: 6
Sources: Page: p.519
Thrombocytopenia grade 4, 16.7%
DLT
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles)
Sources: Page: p.519
unhealthy, 47-78
n = 6
Health Status: unhealthy
Condition: Urothelial bladder cancer
Age Group: 47-78
Sex: M+F
Population Size: 6
Sources: Page: p.519
Neutropenia grade 4, 33.3%
DLT
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Co-administed with::
paclitaxel, i.v(175 mg/m(2) (Day 1), 6 cycles)
Sources: Page: p.519
unhealthy, 47-78
n = 6
Health Status: unhealthy
Condition: Urothelial bladder cancer
Age Group: 47-78
Sex: M+F
Population Size: 6
Sources: Page: p.519
Arrhythmia (NOS) Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Bone marrow failure Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Cardiotoxicity Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Congestive heart failure Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Cystitis hemorrhagic Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Fetal damage Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Hematuria Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Immunosuppression Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Infection Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Metastases Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myelosuppression Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myocarditis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myopericarditis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pericardial effusion Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pneumonitis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary fibrosis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary toxicity Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary veno-occlusive disease Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pyelitis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Respiratory failure Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Toxicity renal Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Ureteritis Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Urinary tract toxicity Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Venoocclusive liver disease Disc. AE
5 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 5 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Arrhythmia (NOS) Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Bone marrow failure Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Cardiotoxicity Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Congestive heart failure Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Cystitis hemorrhagic Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Fetal damage Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Hematuria Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Immunosuppression Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Infection Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Metastases Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myelosuppression Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myocarditis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Myopericarditis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pericardial effusion Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pneumonitis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary fibrosis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary toxicity Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pulmonary veno-occlusive disease Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Pyelitis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Respiratory failure Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Toxicity renal Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Ureteritis Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Urinary tract toxicity Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Venoocclusive liver disease Disc. AE
50 mg/kg multiple, intravenous (total|max)
Recommended
Dose: 50 mg/kg
Route: intravenous
Route: multiple
Dose: 50 mg/kg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hodgkin’s disease| lymphocytic lymphoma| mixed-cell type lymphoma| histiocytic lymphoma| Burkitt’s lymphoma| multiple myeloma| leukemias|mycosis fungoides| neuroblastoma| adenocarcinoma of ovary| retinoblastoma| breast carcinoma
Sources: Page: p.1
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
weak (co-administration study)
Comment: coadministration with ketoconazole: had small effect on CYCLOPHOSPHAMIDE plasma concentration
Page: 15.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes (co-administration study)
Comment: coadministration with ketoconazole: caused a KTZ dose-dependent decrease in main parameters of DECP (Cmax, Tmax, and AUC0–∞) and provided magnitude exposure of DECP (more than a 50% AUC decrease) as a consequence of CYP3A inhibition
PubMed

PubMed

TitleDatePubMed
Carcinoma of the urinary bladder in patients receiving cyclophosphamide.
1975 Aug 7
Remission of active chronic hepatitis after treatment with cyclophosphamide and prednisolone. Report of four cases.
1975 Feb
Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
1981
Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.
2000 Oct
A rapid assay for mitochondrial DNA damage and respiratory chain inhibition in the yeast Saccharomyces cerevisiae.
2001
[Improvement of combination chemotherapy tolerance of human umbilical cord blood CD(34)(+) cells transducted with double drug resistance genes by a bicistronic retroviral vector].
2001 Apr
The chemistry, toxicology, and identification in rat and human urine of 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one: a reactive metabolite in felbamate bioactivation.
2001 Aug
Azathioprine-induced destructive cholangitis.
2001 Feb
Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector.
2001 Feb 1
Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.
2001 Feb 15
Involvement of hypogastric and pelvic nerves for conveying cystitis induced nociception in conscious rats.
2001 Jul
Bladder carcinoma associated with cyclophosphamide therapy for ovarian cancer occurring with a latency of 20 years.
2001 Jul
What is proper treatment for Wegener granulomatosis?
2001 Jul 23
A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.
2001 Jun
Transitional cell carcinoma of the urinary bladder following exposure to cyclophosphamide in childhood.
2001 Jun
Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.
2001 Jun 1
High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome.
2001 Jun 15
Treatment based on a combination of the CYP2B1/cyclophosphamide system and p53 delivery enhances tumour regression in human pancreatic cancer.
2001 Mar
Alterations in neuropeptide expression in lumbosacral bladder pathways following chronic cystitis.
2001 Mar
Hematopoietic stem cell transplantation for high-risk adult patients with severe aplastic anemia; reduction of graft failure by enhancing stem cell dose.
2001 Mar
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
2001 Mar 1
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
2001 Mar 15
Protective effect of berberine on cyclophosphamide-induced haemorrhagic cystitis in rats.
2001 May
Aldehyde-dehydrogenase gene-transduced hematopoietic cell line K562 overcomes the cytoxicity of cyclophosphamide in vitro.
2002 Jun
The in vitro effect of Viscum album (VA) extract on DNA repair of peripheral blood mononuclear cells (PBMC) in cancer patients.
2002 Mar
DNA-dependent protein kinase in leukaemia cells and correlation with drug sensitivity.
2002 May-Jun
N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation.
2003 Aug
Alteration of pharmacokinetics of cyclophosphamide and suppression of the cytochrome p450 genes by ciprofloxacin.
2003 Feb
Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.
2003 Jun
A mouse-based strategy for cyclophosphamide pharmacogenomic discovery.
2003 Oct
Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
2004 Mar
ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat.
2004 Mar
Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
2005 Dec
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.
2006 Jan
Cyclophosphamide enhances TNF-alpha-induced apoptotic cell death in murine vascular endothelial cell.
2006 Mar 6
Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry.
2006 May 1
Pharmacokinetics of N-2-chloroethylaziridine, a volatile cytotoxic metabolite of cyclophosphamide, in the rat.
2006 Oct
Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation.
2007 Jul
Mouse mammary tumor virus promoter-containing retroviral promoter conversion vectors for gene-directed enzyme prodrug therapy are functional in vitro and in vivo.
2008
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.
2008 Jan 1
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.
2008 Jun 1
Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts.
2008 Jun 12
Carbamazepine induces bioactivation of cyclophosphamide and thiotepa.
2009 Feb
Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
2009 Jan
Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model.
2010 Dec
VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.
2010 Dec 15
Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide.
2010 Jun
In vitro investigation into the potential of a mistletoe extract to alleviate adverse effects of cyclophosphamide.
2010 May-Jun
Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+.
2010 Sep 13
A day and night difference in the response of the hepatic transcriptome to cyclophosphamide treatment.
2015 Feb
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Cyclophosphamide can also be administered orally (1 mg per kg per day to 5 mg per kg per day) in malignant diseases.
40-50 mg per kg in divided doses over 2 to 5 days in malignant diseases and 2 mg per kg daily for 8 to 12 weeks in minimal change nephrotic sindrome
Route of Administration: Intravenous
In Vitro Use Guide
Curator's Comment: Cyclophosphamide was tested for its ability to inhibit human lymphocyte proliferation and to modulate lymphocyte response to mitogens in vitro. At higher concentrations (20 to 160 ug/ml), the drug had a suppressive effect with a maximum suppression of 99%.
from 20 to 160 ug/ml
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:55:41 UTC 2023
Edited
by admin
on Sat Dec 16 17:55:41 UTC 2023
Record UNII
8N3DW7272P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYCLOPHOSPHAMIDE
EP   ORANGE BOOK   USP   USP-RS   VANDF   WHO-IP  
EP   USP  
Official Name English
(±)-2-(BIS(2-CHLOROETHYL)AMINO)TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORINE 2-OXIDE MONOHYDRATE
Systematic Name English
CYCLOBLASTIN
Brand Name English
CYCLOPHOSPHAMIDE [MI]
Common Name English
CYCLOPHOSPHAMIDE [WHO-IP]
Common Name English
NSC-756711
Code English
PROCYTOX
Brand Name English
REVIMMUNE
Brand Name English
CYCLOPHOSPHAMIDE [EP MONOGRAPH]
Common Name English
NEOSAR
Brand Name English
CYCLOPHOSPHAMIDUM [WHO-IP LATIN]
Common Name English
CYTOXAN
Brand Name English
ENDOXAN
Brand Name English
CICLOFOSFAMIDE
Common Name English
CYCLOPHOSPHAMIDE [USP-RS]
Common Name English
B-518
Code English
CYTOPHOSPHANE
Common Name English
CYCLOPHOSPHAMIDE [USP MONOGRAPH]
Common Name English
CYCLOPHOSPHANUM [WHO-IP]
Common Name English
ENDOXAN MONOHYDRATE
Common Name English
CYTOPHOSPHAN
Brand Name English
CYCLOPHOSPHAMIDE [VANDF]
Common Name English
2H-1,3,2-OXAZAPHOSPHORIN-2-AMINE, N,N-BIS(2-CHLOROETHYL)TETRAHYDRO-, 2-OXIDE, MONOHYDRATE, (±)-
Common Name English
Cyclophosphamide monohydrate [WHO-DD]
Common Name English
CYCLOSTIN
Brand Name English
CYCLOPHOSPHAMIDE [ORANGE BOOK]
Common Name English
CYCLOPHOSPHAMIDE HYDRATE [JAN]
Common Name English
CYCLOPHOSPHAMIDE MONOHYDRATE
WHO-DD  
Common Name English
CYCLOPHOSPHAMIDE [IARC]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 343611
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
NCI_THESAURUS C697
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
IARC Cyclophosphamide
NDF-RT N0000175558
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
WHO-VATC QL01AA01
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
FDA ORPHAN DRUG 333711
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
WHO-ATC L01AA01
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
NCI_THESAURUS C574
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
FDA ORPHAN DRUG 333911
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
LIVERTOX NBK548059
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
Code System Code Type Description
RXCUI
3002
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY RxNorm
SMS_ID
100000078558
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
IUPHAR
7154
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
EVMPD
SUB16414MIG
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
CYCLOPHOSPHAMIDE
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY Description: A white, crystalline powder.Solubility: Soluble in water; freely soluble in ethanol (~750 g/l) TS; slightly soluble in ether R.Category: Cytotoxic drug.Storage: Cyclophosphamide should be kept in a tightly closed container and stored at a temperature between 2 and 30 ?C.Additional information. CAUTION: Cyclophosphamide must be handled with care, avoiding contact with the skin and inhalation ofairborne particles.
WIKIPEDIA
CYCLOPHOSPHAMIDE
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
RS_ITEM_NUM
1157002
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
EPA CompTox
DTXSID6024888
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
DRUG BANK
DB00531
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
NSC
756711
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
LACTMED
Cyclophosphamide
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
ChEMBL
CHEMBL88
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
FDA UNII
8N3DW7272P
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
DAILYMED
8N3DW7272P
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
MESH
D003520
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
CHEBI
4026
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
NCI_THESAURUS
C405
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
DRUG CENTRAL
758
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
CAS
6055-19-2
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
PUBCHEM
22420
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
MERCK INDEX
m4013
Created by admin on Sat Dec 16 17:55:42 UTC 2023 , Edited by admin on Sat Dec 16 17:55:42 UTC 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
BINDER->LIGAND
BINDING
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
USP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC